Research article · 10 Apr 2025
Conference abstractPublished 5 Dec 2016
How, why and when modified beta cyclodextrins are effective solubilizing tools for parenterals?
Roquette America Inc, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In finding new APIs combinatorial and high throughput chemistry strategies favor leads with hydrophobicity-driven potency properties. API high specificity and potency translates in high cLog P, high molecular weight, high melting point and very low solubility. Formulation scientists have reported myriad of conventional and advanced formulation strategies to improve solubility. However, many of them are still at bench stage because industrial scale equipment is not yet available and is financially difficult to be sustained. In recent years formulator’s attention was focusing on cyclodextrins as a solubilizing tool for their stubborn, like bricks, APIs. The reason is obvious: easy to scale up and a successful presence of parenterals as commercially available brands. This presentation is centered on a coherent approach of insoluble APIs solubilization by modified beta cyclodextrin complexation in liquid phase as well as solid dispersions (spray drying, lyophilization) through an extensive array of case studies (carbamazepine, danazol, albendazole, furosemide, zotepine, zaleplon, lorazepam, progesterone, celecoxib, furosemide, valsartan and NSAIDs (flurbiprofen, ibuprofen, ketoprofen, naproxen, piroxicam). If your API contains more than 5 atoms (C, P, S, and N) to form the skeleton of the drug molecule, less than 5 rings, water solubility is less than 10mg/ ml, melting point temperature is below 250Ã?°C, the molecular weight between 100 and 400 and has stability issues (chemical, photo, etc.) then it is the best candidate for solubilization by cyclodextrin complexation. If API has good performance does not requires solubilization optimization and you are still wondering âÂ?Â?why cyclodextrin complexation? âÂ?Â?one should not forget that they can offer increased stability (physical, chemical), new formulation, patent extension, increased shelf life, etc..
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Endocrinology & Metabolic Syndrome.
Perspective · 22 Jan 2025
Stem Cells of Endocrine Organs in Normal Physiology and Disease
Perspective · 20 Jan 2025
An In-Depth Overview of Reproductive Endocrinology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEndocrinology & Metabolic Syndrome
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Carmen Popescu”

